retatrutide update Eli Lilly’s Phase 3 data is in on Retatrutide! Here’s what they found Big News: GLP-1 Medicine update

Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)

Morning timing also aligns with your natural circadian rhythm of hunger hormones, which peak earlier in the day for most people

Our team is dedicated to guiding you every step of the way to ensure your success

When clinically appropriate, adjunctive therapiesincluding GLP-1based medicationsmay be incorporated as part of a structured, medically supervised plan

Several studies have also suggested that a more uniform distribution of protein across meals is associated with superior anabolic outcomes compared to a skewed pattern